A Phase 2/3 interventional study of SHR7280 tablets and SHR7280 tablets in Uterine Fibroids With Menorrhagia, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Recruiting at 1 site in China. Open to female participants aged 18 Years to 49 Years. Per ClinicalTrials.gov, last updated 2024-01-24.
Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Leiomyoma with a site in China — 19 open to participants now, 22 under way, 2 of them phase 3. Leiomyoma · China.
Among the 39 studies in Leiomyoma with a site in China, this one is the 7th largest by planned enrollment of the 28 interventional ones that give a count, is one of 4 that started in 2022, is one of 2 in phase 2/3, reaches primary completion later than 9 of the 21 other live ones, and was the 14th registered.
438 studies on the registry are indexed under Leiomyoma; 74 are open to participants now.
Browse Leiomyoma studies →19 of the 39 studies in Leiomyoma with a site in China are open now. Recruiting first, the newest first:
Catherin Zhang · Sites in China
Ages 18–75 · Women only
Peking University Aerospace Center Hospital · Sites in China
Women only
Shenzhen Kangzhe Biotechnology Co., Ltd. · Sites in China
Ages 18–50 · Women only
Zhejiang University · Sites in China
Ages 18–65 · Women only
Huazhong University of Science and Technology · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 44 Leiomyoma studies recruiting now, 22 (50%) set no upper age limit and 21 (48%) stop at 75 or younger; 4 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 49 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 7 · Phase 4 3
First in 2008; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 357 is above the median of 66 across 306 interventional studies indexed under Leiomyoma.
Median enrollment 160 across the 28 interventional studies, 200 across the 11 observational. Of the 9 that completed or were terminated, 2 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 39 have an industry lead sponsor. The 10 most frequent:
Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.
Jiangsu HengRui Medicine Co., Ltd. has 4 studies filed under Leiomyoma — fewer than ten, so there is no comparison to draw.
7 of the studies in Leiomyoma with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07860203Catherin ZhangStellate Ganglion Block and Dexmedetomidine for Postoperative Sleep in Women Undergoing Laparoscopic Gynecologic Surgery | 2026-12 |
| NCT06828419Second Affiliated Hospital of Wenzhou Medical UniversityA Clinical Study on the Feasibility and Safety of Abdominal Endoscopic Single-port Surgery System to Assist Gynecological Day Surgery | 2026-12-31 |
| NCT06020924Wenwen WangThe Effects of Uterine Fibroids on Pregnancy in Women | 2026-12-31 |
| NCT05840042Wenwen WangEpidemiology and Risk Factors of Uterine Fibroids in China | 2026-12-31 |
| NCT05386615InSightecPost-Exablate Pregnancy Outcomes Registry Study: Exablate Treatment of Symptomatic Uterine Fibroids | 2026-12-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 39 studies in Leiomyoma with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Phase II:To explore the optimal effective dose of SHR7280 tablets in subjects with menorrhagia with uterine fibroids as a phase III treatment dose.
Phase III:To evaluate the efficacy of the selected dose of SHR7280 compared with placebo in reducing menstrual bleeding in subjects with menorrhagic uterine fibroids in phase II studies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: SHR7280 tablets
Drug: SHR7280 tablets
Drug: PlaceboSHR7280 tablets blank preparation
SHR7280 tablets 300mg for 12 weeks
SHR7280 tablets 400mg for 12 weeks
Placebo group: SHR7280 tablets blank preparation for 12 weeks
Phase one:Percentage of subjects with menstrual bleeding < 80 mL and a reduction of ≥50% from baseline
Time frame: After treatment at week 12
Phase two:Percentage of subjects with menstrual bleeding < 80 mL and a reduction of ≥50% from baseline
Time frame: After treatment at week 24
Percentage of subjects with menstrual bleeding < 80 mL and a reduction of ≥50% from baseline(Phase one)
Time frame: The treatment ended at week 4 and 8
percentage of subjects without menstrual bleeding or spotting (Phase one)
Time frame: The treatment ended at week 4, 8 and 12
Changes in hemoglobin concentration from baseline(Phase one)
Time frame: The treatment ended at week 4, 8 and 12
Changes in uterine volume and maximum fibroid volume from baseline(Phase one)
Time frame: The treatment ended at week 8 and 12
patient global impression of change scale evaluation,The minimum is 1, the maximum is 7, and higher scores mean worse results(Phase one)
Time frame: The treatment ended at week 12
Changes in uterine fibroid symptoms from baseline(Phase one)
Time frame: The treatment ended at week 12
Changes in health related Quality of Life Questionnaire (UFS-QOL) scores from baseline,The minimum is 37 and the maximum is 185, with higher scores indicating worse results(Phase one)
Time frame: The treatment ended at week 12
Number of Participants with Adverse events(Phase one)
Time frame: Stage ⅱ ended, about 30 weeks
The interval between stopping the medication and resuming menstruation(Phase one)
Time frame: Stage ⅱ ended, about 30 weeks
The amount of menstrual bleeding when the medication was stopped until menstruation resumed(Phase one)
Time frame: Stage ⅱ ended, about 30 weeks
Number of days of menstruation from the time of discontinuation of the medication to the time of resumption of menstruation(Phase one)
Time frame: Stage ⅱ ended, about 30 weeks
SHR7280 concentration in plasma(Phase one)
Time frame: Before and at week 4, 8 and 12 after administration
Serum concentrations of estradiol, luteinizing hormone, follicle stimulating hormone and progesterone(Phase one)
Time frame: Before and at week 4, 8 and 12 after administration
Percentage of subjects with menstrual bleeding < 80 mL and a reduction of ≥50% from baseline(Phase two)
Time frame: At the end of weeks 4,8,12,16,20,28,32,36,40,44,48,52
Changes in menstrual bleeding from baseline were assessed using the Alkaline hematin method (AH)(Phase two)
Time frame: At the end of weeks 4,8,12,16,20,24,28,32,36,40,44,48,52
percentage of subjects without menstrual bleeding or spotting (Phase two)
Time frame: Weeks 4,8,12,16,20,24,28,32,36,40,44,48,52
change in Hb concentration from baseline (Phase two)
Time frame: The treatment ended at 4, 8, 12, 16, 20, 24, 36, 44, 52 weeks
Changes in uterine volume and maximum fibroid volume from baseline(Phase two)
Time frame: The treatment ended at weeks 12, 24, and 52
patient global impression of change scale evaluation,The minimum is 1, the maximum is 7, and higher scores mean worse results(Phase two)
Time frame: The treatment ended at weeks 12, 24, and 52
Changes in health related Quality of Life Questionnaire (UFS-QOL) scores from baseline,The minimum is 37 and the maximum is 185, with higher scores indicating worse results(Phase two)
Time frame: The treatment ended at weeks 12, 24, and 52
Number of Participants with Adverse events(Phase two)
Time frame: Stage ⅲ ended at about 74 weeks
The interval between stopping the medication and resuming menstruation(Phase two)
Time frame: Stage ⅲ ended at about 74 weeks
The amount of menstrual bleeding when the medication was stopped until menstruation resumed(Phase two)
Time frame: Stage ⅲ ended at about 74 weeks
Number of days of menstruation from the time of discontinuation of the medication to the time of resumption of menstruation(Phase two)
Time frame: Stage ⅲ ended at about 74 weeks
plasma SHR7280 concentration data(Phase two)
Time frame: Treatment ended at 4, 24, 36, 52 weeks before administration
serum E2, LH, FSH and P concentrations at each point of view(Phase two)
Time frame: Treatment was completed at 4, 8, 12, 16, 20, 24, 36, 44, 52 weeks before administration
Plan to share: Undecided
No publications or documents are linked to this record.
Started Sep 2022 (actual). Primary completion is estimated for Jun 2026, 44 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GnRH Antagonist SHR7280
Jiangsu HengRui Medicine Co., Ltd. →